NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIDDK E-006-2021-0-US-01 COMBINATION THERAPIES FOR COVID-19 (SARS-COV-2) US 63/121,796 Abandoned
NCATS E-096-2018-0-US-08 Process For The Synthesis And Purification Of (2R,6R)-hydroxynorketamine US National Stage 15/734,710 11186539 Issued PDF
NHLBI E-045-2020-0-EP-03 Cyclooxygenase-2 Inhibition For The Treatment Of SAA-high Asthma EP National Stage 20825386.4 Pending
NHLBI E-045-2020-0-PCT-02 Cyclooxygenase-2 Inhibition For The Treatment Of SAA-high Asthma PCT PCT PCT/US2020/063090 Expired
NCI E-028-2015-1-HK-38 Anti-Mutated Kras T Cell Receptors HK EP 42020021375.9 Issued
NCI E-237-2017-1-HK-12 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION HK EP 62020021274.9 Pending
NCI E-237-2017-2-HK-17 T CELL RECEPTORS RECOGNIZING MUTATED P53 HK EP 62020021272.3 Pending
NICHD E-009-2021-0-US-01 THERAPEUTICS AGAINST PATHOGENIC CORONAVIRUSES US 63/119,522 Abandoned
NCI E-098-2018-0-AU-03 T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR AU National Stage 2019263233 Pending
NIAID E-103-2020-0-PCT-02 Improvement Of HIV-neutralizing Antibodies By Modification Of The Heavy Chain FR3 Loop And Other Regions PCT PCT PCT/US2020/062493 Expired
NIAID E-103-2020-0-EP-03 Improvement Of HIV-neutralizing Antibodies By Modification Of The Heavy Chain FR3 Loop And Other Regions EP National Stage 20892529.7 Pending
NCI E-182-2017-0-HK-12 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION HK EP 62020020943.0 Issued
NCATS E-026-2016-0-AU-21 Compounds for Improving MRNA Splicing AU DIV 2020277224 Abandoned
NCI E-040-2012-0-HK-57 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen HK EP 42020020967.4 Pending
NCI E-044-2020-0-PCT-02 METHODS OF IDENTIFYING CELL-TYPE-SPECIFIC GENE EXPRESSION LEVELS BY DECONVOLVING BULK GENE EXPRESSION PCT PCT PCT/US2020/062238 Expired
NCATS E-095-2018-0-EP-04 QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS EP National Stage 19726848.5 Pending
NCI E-103-2021-0-KR-06 USE OF LENTIVECTOR TRANSDUCED T-RAPA CELLS FOR AMELIORATION OF LYSOSOMAL STORAGE DISORDERS KR National Stage 10-2020-7034012 Pending
NCI E-176-2014-0-HK-55 EXPRESSION VECTORS FOR ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS HK EP 42020020661.3 Pending
NCI E-078-2016-0-US-05 RNA/DNA HYBRID NANOPARTICLES MODIFIED WITH SINGLE STRANDED RNA TOEHOLDS AND USES THEREOF US DIV 17/102,786 Abandoned
NCI E-176-2014-0-US-57 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS US CON 17/101,360 11434272 Issued PDF
NCI E-098-2018-0-EP-05 T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR EP National Stage 19723615.1 Pending
NIAID E-191-2018-0-US-03 Improved Methods Of Manufacturing Peptide-Based Vaccines US National Stage 17/057,658 Pending
NCI E-151-2019-0-EP-01 TASPASE1 INHIBITORS AND USES THEREOF EP National Stage 20889515.1 Pending
NCI E-151-2019-0-AU-01 TASPASE1 INHIBITORS AND USES THEREOF AU National Stage 2020386081 Pending
NCI E-151-2019-0-JP-01 TASPASE1 INHIBITORS AND USES THEREOF JP National Stage 2022-529821 Pending
NIAID E-131-2020-6-US-01 Anti-Coronavirus Antibodies And Methods Of Use US 63/116,483 Abandoned
NCI E-151-2019-0-CN-01 TASPASE1 INHIBITORS AND USES THEREOF CN National Stage 202080092864.4 Pending
NCI E-151-2019-0-PCT-02 TASPASE1 INHIBITORS AND USES THEREOF PCT PCT PCT/US2020/061657 Expired
NIAID E-357-2001-1-US-34 CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS US DIV 16/952,864 11400150 Expired PDF
NCI E-094-2018-0-AU-03 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF AU National Stage 2019260656 Pending
NIAID E-021-2021-0-US-01 NOVEL VAR2CSA IMMUNOGENS AND METHODS OF USE THEREOF US 63/115,729 Abandoned
NIEHS E-241-2020-0-US-01 Massively Paralleled Multi-patient Assay For Pathogenic Infection Diagnosis And Host Physiology Surveillance Using Nucleic Acid Sequencing US 63/116,031 Abandoned
NCI E-184-2009-0-US-02 Combination Immunotherapy Compositions And Methods US CON 16/951,739 11596675 Issued PDF
NCI E-042-2014-0-JP-27 Chimeric Antigen Receptors Targeting CD-19 JP DIV 2020-191748 Issued
NCI E-202-2020-0-US-01 TYROSYL-LOCK PEPTIDES US 63/115,418 Abandoned
NCATS E-234-2020-0-US-01 Small Molecule Inhibitors of SARS-CoV-2 US 63/115,288 Abandoned
NCI E-023-2019-0-PCT-02 INHIBITORS OF HISTONE DEMETHYLASES PCT PCT PCT/US2020/060955 Expired
NIAID E-018-2018-0-KR-11 CHIMERIC VECTORS KR National Stage 2020-7033157 Pending
NCATS E-128-2019-0-PCT-02 SALTS OF (2R, 6R)-HYDROXYNORKETAMINE, THEIR CRYSTAL FORMS, AND METHODS OF MAKING THE SAME PCT PCT PCT/US2020/060848 Expired
NCATS E-128-2019-0-EP-05 SALTS OF (2R, 6R)-HYDROXYNORKETAMINE, THEIR CRYSTAL FORMS, AND METHODS OF MAKING THE SAME EP National Stage 20824741.1 Pending
NCI E-226-2014-0-EP-09 ANTI-THYROGLOBULIN T CELL RECEPTORS EP DIV 20208238.4 Pending
NCATS E-128-2019-0-JP-06 SALTS OF (2R, 6R)-HYDROXYNORKETAMINE, THEIR CRYSTAL FORMS, AND METHODS OF MAKING THE SAME JP National Stage 2022-528974 Pending
NCATS E-010-2022-0-US-01 Protein And Lipid Therapeutic Targets US 63/114,760 Abandoned
NCATS E-128-2019-0-AU-03 SALTS OF (2R, 6R)-HYDROXYNORKETAMINE, THEIR CRYSTAL FORMS, AND METHODS OF MAKING THE SAME AU National Stage 2020387937 Pending
NCATS E-128-2019-0-CA-04 SALTS OF (2R, 6R)-HYDROXYNORKETAMINE, THEIR CRYSTAL FORMS, AND METHODS OF MAKING THE SAME CA National Stage 3161001 Pending
NIAID E-139-2006-0-BR-69 Development Of Dengue Virus Vaccine Components BR DIV BR122020023372-9 Issued
NIAID E-139-2006-0-BR-68 Development Of Dengue Virus Vaccine Components BR DIV BR122020023371-0 Pending
NCATS E-114-2018-0-JP-06 FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS JP National Stage 2020-564095 Issued
NCATS E-114-2018-0-US-07 FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS US National Stage 17/055,256 Abandoned
NIAID E-018-2018-0-EP-08 CHIMERIC VECTORS EP National Stage 19729386.3 Pending